Mzee (@mzeengunga) header
Mzee (@mzeengunga) profile picture

The world is not enough

Nairobi, Kenya
Joined September 2016
Photo by Mzee (@mzeengunga)Photo by Mzee (@mzeengunga)Photo by Mzee (@mzeengunga)Photo by Mzee (@mzeengunga)Photo by Mzee (@mzeengunga)Photo by Mzee (@mzeengunga)Photo by Mzee (@mzeengunga)Photo by Mzee (@mzeengunga)Photo by Mzee (@mzeengunga)Photo by Mzee (@mzeengunga)
No single imaging test captures all forms of right ventricular dysfunction in valve disease. New #JACC review: integrate imaging and hemodynamics, especially in tricuspid regurgitation. #cvVHD @OmarChehab1 @spinneymd @XGalloo @GAilawadiMD bit.ly/3UVSxYc
39
1
148
7,001
Mzee retweeted
A trial of venous thromboembolism (VTE) prophylaxis after hip or knee arthroplasty did not show that aspirin was noninferior to rivaroxaban or warfarin for symptomatic VTE or death. Warfarin and rivaroxaban were not noninferior to aspirin for safety. Full PEPPER trial results and Research Summary: nej.md/4iIxVL0
6
60
6
227
34,278
Balancing the Weight of Manhood: Men are often there for everyone. But who is there for them? Join our panelists and speakers for an honest conversation about support, shared responsibility and navigating the realities of modern manhood. Register to attend below:

40
87
12
513
918,183
Cardiovascular imaging is not about acquiring more images. It is about answering the right clinical question. At yesterday’s Nairobi Cardiovascular Imaging Symposium, we explored multimodality precision, structured reporting and equitable access. The right test. The first time. @kenyacardiacs @PASCAR_Cardio @mzeengunga
1
1
100
The right image. The right question. The right clinical decision. Precision cardiovascular imaging is not just about what we see, but how it changes management. Join us at the KCS–PASCAR Imaging Symposium, Nairobi | 14 Nov. forms.gle/WoTF6m5ve7eFDvZ37 #CVImaging @kenyacardiacs @PASCAR_Cardio @mzeengunga
1
2
105
Mzee retweeted
Presented at #ScientificSessions26: Among patients with cardiovascular disease and high lipoprotein(a) levels, pelacarsen lowered the lipoprotein(a) level, but the risk of major cardiovascular events was similar with pelacarsen and placebo. Full phase 3 Lp(a)HORIZON trial results: nej.md/4AcZL9n @AHAScience
15
120
31
339
53,941
Mzee retweeted
Presented at #TCT2026: In patients with moderate aortic stenosis and high-risk features, the percentage who died or had a heart-failure event within 2 years was lower with transcatheter aortic-valve replacement than with surveillance (16.7% vs. 23.9%). Full PROGRESS trial results: nej.md/4eUv9kA @crfheart
8
113
19
313
599,904
Evidence alone does not transform health systems. Privileged to have helped shape the Nairobi Declaration on African Women's Cardiovascular Health. Five commitments. One imperative: translate evidence into equitable care and measurable outcomes. The next chapter is implementation. @kenyacardiacs @Apog_Kenya @MOH_Kenya @WomenAs1 @worldheartfed
1
2
2
172
Menopause is an important opportunity to reassess cardiovascular risk. Menopausal hormone therapy requires individualised assessment and shared decision-making. It is not a strategy for cardiovascular prevention. Women's heart health demands better integration of evidence across specialties. #WomensHeartHealth @kenyacardiacs @Apog_Kenya
1
7
269
Behind every cardiovascular statistic is a woman, a story and a life worth protecting. These patient advocates remind us why women's heart health matters. From evidence to action. From survival to quality of life. Progress is measured in lives improved, not conferences convened. #WomensHeartHealth @kenyacardiacs @Apog_Kenya @mzeengunga @Starlight_Bo @WomenAs1 @worldheartfed
1
1
12
415
Pregnancy is not just nine months. It is a cardiovascular health story that spans a woman’s lifetime. Dr. Bosire compares a woman’s journey to an F1 race, navigating different challenges through adolescence, pregnancy &menopause. #KCS #APOGKenya #Africanwomenshearthealthsymposium
4
5
102
Understanding #POTS starts with trusted information. CardioSmart’s POTS hub offers patient-friendly information on symptoms, diagnosis, treatment, questions to ask the care team and self-advocacy. Check out the hub here: bit.ly/4y8Bhgb #CardioSmart #POTSAwarenessDay
1
14
43
3,382
Dr. Barasa takes the delegates through #peripartum #cardiomyopathy, a condition that affects the heart around the end of pregnancy or in the months following delivery. Recognising it early and ensuring timely assessment and care are essential #WomensHeartHealth #KCS #APOGKenya
4
3
67
SCAD calls for careful, individualised management Dr. Ngunga discusses (SCAD), including recommendations for mild to moderate physical activity & delicate decisions involved in management, including PCI #KCS #APOGKenya #Africanwomenshearthealthsymposium
4
4
93
During the 2nd panel discussion, Dr. Bosire, highlights the need to strengthen pre-menopausal care, address gaps in evidence on cardiovascular outcomes, &develop policies that make quality care &treatment more accessible &affordable in Kenya. #WomensHeartHealth #KCS #APOGKenya
4
4
64
Dr. Ngunga points to the need for public awareness of #cardiovascular risks, alongside the work health professionals are doing. Raises concerns about #environmentaltoxins, resources needed to address chronic conditions, & policies required to support #research and innovation.
4
5
65
🫀Finerenone vs spironolactone in heart failure with mildly reduced or preserved ejection fraction: a real-world study. see@ ow.ly/LcYk5100u04 @EJHFEiC @AmrAbdin10 @GiuseppeGalati_ @HanCardiomd @EJHFEiC @JanBiegus @ppponikowski #HFA_ESC @hvanspall @FudimMarat @gcfmd @MarcoMetra @GianluSava #ESCHeartFailure
3
142
8
413
37,606
💊 Can SGLT2 inhibitors improve outcomes in transthyretin cardiac #Amyloidosis? A #JACCAdvances meta-analysis of 14 observational studies (n=10,852) found #SGLT2i use was associated with 56% lower all-cause mortality & 38% lower HF hospitalization. bit.ly/4sjrhPO
4
45
1
116
6,725